Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

(Reuters) – The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc’s Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company’s shares down more than 70 percent before the opening bell.


Source: Reuters Health